David Ricks, Chair and CEO of Eli Lilly, joins Scott to discuss the rise of GLP-1 drugs, the future of obesity treatment, and why America’s healthcare system is facing a crisis of trust. They explore healthcare costs, addiction, unregulated peptides, pharmaceutical innovation, and the role AI could play in the next generation of drug discovery.
Looking for the full version? Become a Prof G+ subscriber for unlimited, ad-free access to all our videos, including exclusive content only available on Substack.
